Here, we describe the history and challenges of managing our patient and the development of an insulin desensitization protocol in a resource-limited setup.<h4>Case summary</h4>A 42-year-old Sudanese woman with poorly controlled type 2 diabetes on maximum antidiabetic medications required insulin therapy to achieve reasonable glycemic control. The gene discussed is INS; the disease is type 2 diabetes mellitus.